1. GuzmanMG, HalsteadSB, ArtsobH, BuchyP, FarrarJ, et al. (2010) Dengue: a continuing global threat. Nat Rev Microbiol 8: S7–16.
2. MackeyTK, LiangBA (2012) Threats from emerging and re-emerging neglected tropical diseases (NTDs). Infect Ecol Epidemiol 2: 10.3402/iee.v3402i3400.18667.
3. BhattS, GethingPW, BradyOJ, MessinaJP, FarlowAW, et al. (2013) The global distribution and burden of dengue. Nature 496: 504–507.
4. VaughnDW, GreenS, KalayanaroojS, InnisBL, NimmannityaS, et al. (2000) Dengue viremia titer, antibody response pattern, and virus serotype correlate with disease severity. J Infect Dis 181: 2–9.
5. HalsteadSB (2003) Neutralization and antibody-dependent enhancement of dengue viruses. Adv Virus Res 60: 421–467.
6. HalsteadSB, NimmannityaS, CohenSN (1970) Observations related to pathogenesis of dengue hemorrhagic fever. IV. Relation of disease severity to antibody response and virus recovered. Yale J Biol Med 42: 311–328.
7. ChauTN, QuyenNT, ThuyTT, TuanNM, HoangDM, et al. (2008) Dengue in Vietnamese infants–results of infection-enhancement assays correlate with age-related disease epidemiology, and cellular immune responses correlate with disease severity. J Infect Dis 198: 516–524.
8. KliksSC, NimmanityaS, NisalakA, BurkeDS (1988) Evidence that maternal dengue antibodies are important in the development of dengue hemorrhagic fever in infants. Am J Trop Med Hyg 38: 411–419.
9. ChauTN, HieuNT, AndersKL, WolbersM, Lien leB, et al. (2009) Dengue virus infections and maternal antibody decay in a prospective birth cohort study of Vietnamese infants. J Infect Dis 200: 1893–1900.
10. Rodenhuis-ZybertIA, van der SchaarHM, da Silva VoorhamJM, van der Ende-MetselaarH, LeiHY, et al. (2010) Immature dengue virus: a veiled pathogen? PLoS Pathog 6: e1000718.
11. UbolS, HalsteadSB (2010) How innate immune mechanisms contribute to antibody-enhanced viral infections. Clin Vaccine Immunol 17: 1829–1835.
12. ChareonsirisuthigulT, KalayanaroojS, UbolS (2007) Dengue virus (DENV) antibody-dependent enhancement of infection upregulates the production of anti-inflammatory cytokines, but suppresses anti-DENV free radical and pro-inflammatory cytokine production, in THP-1 cells. J Gen Virol 88: 365–375.
13. BoonnakK, DambachKM, DonofrioGC, TassaneetrithepB, MarovichMA (2011) Cell type specificity and host genetic polymorphisms influence antibody-dependent enhancement of dengue virus infection. J Virol 85: 1671–1683.
14. KouZ, LimJY, BeltramelloM, QuinnM, ChenH, et al. (2011) Human antibodies against dengue enhance dengue viral infectivity without suppressing type I interferon secretion in primary human monocytes. Virology 410: 240–247.
15. RolphMS, ZaidA, RulliNE, MahalingamS (2011) Downregulation of interferon-beta in antibody-dependent enhancement of dengue viral infections of human macrophages is dependent on interleukin-6. J Infect Dis 204: 489–491.
16. HalsteadSB, ShotwellH, CasalsJ (1973) Studies on the pathogenesis of dengue infection in monkeys. II. Clinical laboratory responses to heterologous infection. J Infect Dis 128: 15–22.
17. GoncalvezAP, EngleRE, St ClaireM, PurcellRH, LaiCJ (2007) Monoclonal antibody-mediated enhancement of dengue virus infection in vitro and in vivo and strategies for prevention. Proc Natl Acad Sci U S A 104: 9422–9427.
18. UbolS, PhukliaW, KalayanaroojS, ModhiranN (2010) Mechanisms of immune evasion induced by a complex of dengue virus and preexisting enhancing antibodies. J Infect Dis 201: 923–935.
19. ModhiranN, KalayanaroojS, UbolS (2010) Subversion of innate defenses by the interplay between DENV and pre-existing enhancing antibodies: TLRs signaling collapse. PLoS Negl Trop Dis 4: e924.
20. SchlesingerRW (1977) Dengue viruses. Virol Monogr 1–132.
21. RautCG, DeolankarRP, KolhapureRM, GoverdhanMK (1996) Susceptibility of laboratory-bred rodents to the experimental infection with dengue virus type 2. Acta Virol 40: 143–146.
22. JohnsonAJ, RoehrigJT (1999) New mouse model for dengue virus vaccine testing. J Virol 73: 783–786.
23. ZellwegerRM, PrestwoodTR, ShrestaS (2010) Enhanced infection of liver sinusoidal endothelial cells in a mouse model of antibody-induced severe dengue disease. Cell Host Microbe 7: 128–139.
24. ShrestaS, ShararKL, PrigozhinDM, BeattyPR, HarrisE (2006) Murine model for dengue virus-induced lethal disease with increased vascular permeability. J Virol 80: 10208–10217.
25. BalsitisSJ, WilliamsKL, LachicaR, FloresD, KyleJL, et al. (2010) Lethal antibody enhancement of dengue disease in mice is prevented by Fc modification. PLoS Pathog 6: e1000790.
26. BeltramelloM, WilliamsKL, SimmonsCP, MacagnoA, SimonelliL, et al. (2010) The human immune response to Dengue virus is dominated by highly cross-reactive antibodies endowed with neutralizing and enhancing activity. Cell Host Microbe 8: 271–283.
27. de AlwisR, BeltramelloM, MesserWB, Sukupolvi-PettyS, WahalaWM, et al. (2011) In-depth analysis of the antibody response of individuals exposed to primary dengue virus infection. PLoS Negl Trop Dis 5: e1188.
28. DejnirattisaiW, JumnainsongA, OnsirisakulN, FittonP, VasanawathanaS, et al. (2010) Cross-reacting antibodies enhance dengue virus infection in humans. Science 328: 745–748.
29. SmithSA, ZhouY, OlivarezNP, BroadwaterAH, de SilvaAM, et al. (2012) Persistence of circulating memory B cell clones with potential for dengue virus disease enhancement for decades following infection. J Virol 86: 2665–2675.
30. SmithSA, de AlwisR, KoseN, DurbinAP, WhiteheadSS, et al. (2013) Human monoclonal antibodies derived from memory B cells following live attenuated dengue virus vaccination or natural infection exhibit similar characteristics. Journal of Infectious Diseases 207: 1898–1908.
31. de AlwisR, SmithSA, OlivarezNP, MesserWB, HuynhJP, et al. (2012) Identification of human neutralizing antibodies that bind to complex epitopes on dengue virions. Proc Natl Acad Sci U S A 109: 7439–7444.
32. RoehrigJT, BolinRA, KellyRG (1998) Monoclonal antibody mapping of the envelope glycoprotein of the dengue 2 virus, Jamaica. Virology 246: 317–328.
33. SmithSA, de AlwisAR, KoseN, HarrisE, IbarraKD, et al. (2013) The potent and broadly neutralizing human dengue virus-specific monoclonal antibody 1C19 reveals a unique cross-reactive epitope on the bc loop of domain II of the envelope protein. MBio 4: e00873–00813.
34. LaiCY, TsaiWY, LinSR, KaoCL, HuHP, et al. (2008) Antibodies to envelope glycoprotein of dengue virus during the natural course of infection are predominantly cross-reactive and recognize epitopes containing highly conserved residues at the fusion loop of domain II. J Virol 82: 6631–6643.
35. LaiCY, WilliamsKL, WuYC, KnightS, BalmasedaA, et al. (2013) Analysis of cross-reactive antibodies recognizing the fusion loop of envelope protein and correlation with neutralizing antibody titers in Nicaraguan dengue cases. PLoS Negl Trop Dis 7: e2451.
36. LuoYY, FengJJ, ZhouJM, YuZZ, FangDY, et al. (2013) Identification of a novel infection-enhancing epitope on dengue prM using a dengue cross-reacting monoclonal antibody. BMC Microbiol 13: 194.
37. ChanAH, TanHC, ChowAY, LimAP, LokSM, et al. (2012) A human PrM antibody that recognizes a novel cryptic epitope on dengue E glycoprotein. PLoS One 7: e33451.
38. LiL, LokSM, YuIM, ZhangY, KuhnRJ, et al. (2008) The flavivirus precursor membrane-envelope protein complex: structure and maturation. Science 319: 1830–1834.
39. SongKY, ZhaoH, LiSH, LiXF, DengYQ, et al. (2013) Identification and characterization of a linearized B-cell epitope on the pr protein of dengue virus. J Gen Virol 94: 1510–1516.
40. WilliamsKL, Sukupolvi-PettyS, BeltramelloM, JohnsonS, SallustoF, et al. (2013) Therapeutic efficacy against lethal dengue virus infection of antibodies lacking Fcγreceptor binding is due to neutralizing potency and blocking of enhancing antibodies. PLoS Pathog 9: e1003157.
41. JunjhonJ, EdwardsTJ, UtaipatU, BowmanVD, HoldawayHA, et al. (2010) Influence of pr-M cleavage on the heterogeneity of extracellular dengue virus particles. J Virol 84: 8353–8358.
42. TeohEP, KukkaroP, TeoEW, LimAP, TanTT, et al. (2012) The structural basis for serotype-specific neutralization of dengue virus by a human antibody. Sci Transl Med 4: 139ra183.
43. VanblarganLA, MukherjeeS, DowdKA, DurbinAP, WhiteheadSS, et al. (2013) The type-specific neutralizing antibody response elicited by a dengue vaccine candidate is focused on two amino acids of the envelope protein. PLoS Pathog 9: e1003761.
44. MesserWB, de AlwisR, YountBL, RoyalSR, HuynhJP, et al. (2014) Dengue virus envelope protein domain I/II hinge determines long-lived serotype-specific dengue immunity. Proc Natl Acad Sci U S A 111: 1939–1944.
45. LittauaR, KuraneI, EnnisFA (1990) Human IgG Fc receptor II mediates antibody-dependent enhancement of dengue virus infection. J Immunol 144: 3183–3186.
46. RodrigoWW, JinX, BlackleySD, RoseRC, SchlesingerJJ (2006) Differential enhancement of dengue virus immune complex infectivity mediated by signaling-competent and signaling-incompetent human Fcgamma RIA (CD64) or FcgammaRIIA (CD32). J Virol 80: 10128–10138.
47. ChanKR, ZhangSL, TanHC, ChanYK, ChowA, et al. (2011) Ligation of Fc gamma receptor IIB inhibits antibody-dependent enhancement of dengue virus infection. Proc Natl Acad Sci U S A 108: 12479–12484.
48. BoonnakK, SlikeBM, DonofrioGC, MarovichMA (2013) Human FcgammaRII cytoplasmic domains differentially influence antibody-mediated dengue virus infection. J Immunol 190: 5659–5665.
49. BruhnsP, IannascoliB, EnglandP, MancardiDA, FernandezN, et al. (2009) Specificity and affinity of human Fcgamma receptors and their polymorphic variants for human IgG subclasses. Blood 113: 3716–3725.
50. BruhnsP (2012) Properties of mouse and human IgG receptors and their contribution to disease models. Blood 119: 5640–5649.
51. GarciaG, SierraB, PerezAB, AguirreE, RosadoI, et al. (2010) Asymptomatic dengue infection in a Cuban population confirms the protective role of the RR variant of the FcgammaRIIa polymorphism. Am J Trop Med Hyg 82: 1153–1156.
52. PrestwoodTR, PrigozhinDM, ShararKL, ZellwegerRM, ShrestaS (2008) A mouse-passaged dengue virus strain with reduced affinity for heparan sulfate causes severe disease in mice by establishing increased systemic viral loads. J Virol 82: 8411–8421.
53. WahalaWM, KrausAA, HaymoreLB, Accavitti-LoperMA, de SilvaAM (2009) Dengue virus neutralization by human immune sera: role of envelope protein domain III-reactive antibody. Virology 392: 103–113.
54. LinHE, TsaiWY, LiuIJ, LiPC, LiaoMY, et al. (2012) Analysis of epitopes on dengue virus envelope protein recognized by monoclonal antibodies and polyclonal human sera by a high throughput assay. PLoS Negl Trop Dis 6: e1447.
55. WilliamsKL, WahalaWM, OrozcoS, de SilvaAM, HarrisE (2012) Antibodies targeting dengue virus envelope domain III are not required for serotype-specific protection or prevention of enhancement in vivo. Virology 429: 12–20.
56. OrozcoS, SchmidMA, ParameswaranP, LachicaR, HennMR, et al. (2012) Characterization of a model of lethal dengue virus 2 infection in C57BL/6 mice deficient in the alpha/beta interferon receptor. J Gen Virol 93: 2152–2157.